INDOCO
Indoco Remedies
Each stock's 10,000-path forecast, rendered as light.
Indoco Remedies (INDOCO) Stock Analysis & Case Study
Is INDOCO a good buy? The data-driven verdict.
Indoco Remedies (INDOCO) trades at ₹236,on the numbers it high-risk on the numbers, a Downstox Snapshot Score of 24/100.
On the numbers, Indoco Remedies (INDOCO) high-risk on the numbers, a Downstox Snapshot Score of 24/100, weighing expensive at 102.0× earnings, ROE of -9.4%, a 28% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
INDOCO fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is INDOCO overvalued? INDOCO P/E vs its sector
INDOCO's P/E of 102.0× sits above the sector peer median of 15.9×, so on earnings it screens richer than peers, while its 0.08% dividend yield is below the peer median of 1.65%.
INDOCO share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.0y of INDOCO history (-17%/yr drift, 45%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| INDOCO 2027 | ₹103 | ₹180 | ₹318 | -23% |
| INDOCO 2028 | ₹62 | ₹136 | ₹305 | -42% |
| INDOCO 2029 | ₹39 | ₹104 | ₹284 | -56% |
| INDOCO 2030 | ₹26 | ₹80 | ₹253 | -66% |
| INDOCO 2031 | ₹17 | ₹61 | ₹220 | -74% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability INDOCO goes up, or doubles?
The bull case for INDOCO
- Indoco Remedies is part of the nifty500 universe with live, tracked fundamentals on Downstox.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹284.
The bear case & risks
- A rich 102.0× P/E leaves a thin margin of safety if growth slows.
- A low Piotroski F-Score of 3/9 flags weaker financial health this cycle, worth understanding why before committing.
- The probability model is cautious 12 months out, only a 28% chance of finishing above today's price.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹39.
INDOCO volatility & expected range, how bumpy is the ride?
Over the last 2.0 years INDOCO compounded at -17%/year with annualized volatility of 45%. That volatility implies a 1-year 80% range of ₹103–₹318, the honest backbone behind any single price target.
INDOCO price forecast, the full 60-month probability fan
INDOCO price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds INDOCO hits common targets within the simulated horizon?
Full multi-horizon detail on the INDOCO price target & forecast page.
INDOCO Piotroski F-Score: 3/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. INDOCO scores 3/9,weak on the financial-strength checks.
INDOCO MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy INDOCO with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| UpstoxCHEAPEST | 37.3% | 2.7× |
| Zerodha | 50.0% | 2.0× |
| Dhan | 40.0% | 2.5× |
Compare every broker on the INDOCO MTF page.
INDOCO vs peers,sector comparison
About Indoco Remedies: sector, index & market-cap context
Indoco Remedies (INDOCO) is a small-cap NSE-listed company, and a constituent of the Nifty 500 index group, with a market capitalisation of ₹2,177 Cr. See more Nifty 500 stocks.
How the INDOCO Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Indoco Remedies's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
INDOCO analysis, FAQs
Is Indoco Remedies (INDOCO) a good buy?
On the numbers, Indoco Remedies (INDOCO) high-risk on the numbers, a Downstox Snapshot Score of 24/100, weighing expensive at 102.0× earnings, ROE of -9.4%, a 28% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is INDOCO overvalued or undervalued?
INDOCO trades at 102.0× earnings versus a peer median of 15.9×, so it screens richer than its sector peers.
What is the INDOCO share price target for 2031?
INDOCO's probability-weighted 2031 median target is ₹61, with an 80% range of ₹17–₹220 (10,000-path Monte-Carlo).
What is the probability INDOCO doubles in 5 years?
The modelled probability of INDOCO reaching ₹470 (2×) within 5 years is 2%.
What is the bull case for INDOCO?
Indoco Remedies is part of the nifty500 universe with live, tracked fundamentals on Downstox.
What are the risks in INDOCO?
A rich 102.0× P/E leaves a thin margin of safety if growth slows. A low Piotroski F-Score of 3/9 flags weaker financial health this cycle, worth understanding why before committing. The probability model is cautious 12 months out, only a 28% chance of finishing above today's price.